Uterine Malignant Mixed Mesodermal Tumor

Uterine carcinosarcoma is a rare, very aggressive cancer of the womb (uterus). It looks like a “mixed” tumor because it has two parts at the same time: a carcinoma (cancer from inner lining gland cells) and a sarcoma (cancer from connective or muscle-type cells). Today, experts usually group it with high-grade endometrial cancers and stage it using the same FIGO endometrial system. The disease often spreads early and needs combined treatment, usually surgery first and then chemotherapy, sometimes with radiation and, in selected cases, immunotherapy. Cancer.gov+2figo.org+2 Doctors cannot point to one single cause, but several factors increase risk: older age, past exposure to pelvic radiation, obesity and estrogen exposure without progesterone balance, and certain molecular features similar to other high-risk endometrial cancers. Prior tamoxifen use for breast cancer also raises risk slightly. Most patients are post-menopausal. Because this tumor behaves biologically like a very high-grade endometrial cancer, modern staging and risk grouping now follow the FIGO 2023 endometrial rules. Cancer.gov+2figo.org+2

Uterine malignant mixed mesodermal tumour is a rare, very aggressive cancer that starts in the body of the uterus (the womb). It has two parts inside the same tumour:

1. a carcinoma part (cancer from the lining cells of the uterus called endometrium), and

2. a sarcoma part (cancer from tissue that looks like muscle, bone, or other supporting tissues).

Because it mixes “carcino-” (epithelial) and “sarcoma” (mesenchymal) elements, doctors call it a “carcinosarcoma”. Today many experts think the carcinoma part is the “driver” and the sarcomatous part grows from it later (called epithelial–mesenchymal transition). This tumour behaves more like a very high-grade endometrial carcinoma than like other pure sarcomas, and it tends to spread early and come back after treatment. It is uncommon but serious. PMC+2IARC Publications+2

Other names

• Uterine carcinosarcoma

• Malignant mixed Müllerian tumour (MMMT)

• Malignant mixed mesodermal tumour
  These names all point to the same disease: a uterine cancer made of both carcinoma and sarcoma components. Major cancer groups and pathology books still use “carcinosarcoma (MMMT)” in guidelines and classifications. PubMed+1

Types

Doctors often describe carcinosarcoma by the kind of sarcoma-like tissue inside it and by what the carcinoma part looks like.

By sarcomatous component

• Homologous type: the sarcoma part looks like tissues normally found in the uterus, such as high-grade endometrial stromal sarcoma or leiomyosarcoma-like areas.

• Heterologous type: the sarcoma part shows tissues not normally in the uterus, such as cartilage (chondrosarcoma), bone (osteosarcoma), skeletal muscle (rhabdomyosarcoma), or fat (liposarcoma).
  Either pattern can occur; heterologous elements do not automatically mean a worse stage, but they help pathologists name the tumour correctly. PMC

By epithelial (carcinoma) component

• Serous carcinoma-like (very aggressive, p53-abnormal is common)

• High-grade endometrioid carcinoma-like

• Clear cell carcinoma-like
  The epithelial half often dictates behaviour and response to treatment; many guidelines now manage carcinosarcoma within high-risk endometrial carcinoma pathways. PubMed+1

---

Causes and risk factors

Carcinosarcoma does not have a single cause. The following risk factors make it more likely. Each factor increases risk; having one does not mean a person will get the disease.

1. Older age: Most patients are post-menopausal; risk rises after age 60. Age allows more genetic damage to build up. SEER

2. Long-term unopposed estrogen exposure: Estrogen stimulates the uterine lining; without progesterone balance, abnormal cells can grow. (Examples: estrogen-only HRT in women with a uterus, certain ovarian tumours producing estrogen.) Cancer.gov

3. Prior pelvic radiation therapy: Radiation can damage DNA in uterine cells; cancers may appear years later. Cancer.gov

4. Tamoxifen use: Tamoxifen acts like estrogen in the uterus and can raise risk of aggressive endometrial cancers, including carcinosarcoma, after long use. Cancer.gov

5. Obesity: More body fat converts hormones into estrogen, raising endometrial stimulation and cancer risk. Cancer.gov

6. Diabetes and insulin resistance: These conditions link to chronic inflammation and hormone changes that may favor cancer growth. Cancer.gov

7. Nulliparity (never giving birth): More lifetime menstrual cycles mean longer estrogen exposure to the endometrium. Cancer.gov

8. Early first period or late menopause: Extends years of estrogen exposure. Cancer.gov

9. Genetic pathway: p53 abnormalities: Many carcinosarcomas show TP53 mutations, driving aggressive behaviour. (This is a tumour feature, not a lifestyle cause.) PMC

10. Lynch syndrome (rare association): Mismatch repair gene defects raise endometrial cancer risk in general; carcinosarcoma can occur but is less typical. PubMed

11. Family history of uterine/ovarian cancers: May reflect shared genetics or hormonal environments. Cancer.gov

12. African ancestry (population risk difference): Some epidemiology shows higher rates and worse outcomes, likely from biology plus care access differences. BMJ Open

13. Prior endometrial hyperplasia or carcinoma: A high-grade carcinoma can transform into carcinosarcoma through epithelial–mesenchymal transition. PMC

14. Chronic inflammation of the uterus: Inflammation can promote DNA damage and abnormal repair. Cancer.gov

15. Smoking: Contributes to DNA damage and reduced immune surveillance; links are weaker than for other cancers but still relevant. Cancer.gov

16. Low physical activity: Indirectly increases risk by influencing weight, insulin, and estrogen levels. Cancer.gov

17. Diet high in processed foods and low in fibre: May worsen obesity/insulin resistance; evidence is general for endometrial cancer risk. Cancer.gov

18. Prolonged anovulation (e.g., PCOS): Long periods without ovulation mean constant estrogen effect without progesterone. Cancer.gov

19. Environmental carcinogens (e.g., prior chemotherapy/radiation): DNA-damaging exposures can play a role over time. Cancer.gov

20. Impaired immune surveillance with aging: The body may be less able to remove abnormal cells, allowing tumours to form. Cancer.gov

---

Common symptoms

Symptoms often mimic other uterine problems. Any post-menopausal bleeding needs urgent assessment.

1. Abnormal uterine bleeding: The most common sign—spotting or heavy bleeding after menopause or between periods. The tumour erodes the lining and blood vessels. Cancer.gov

2. Watery or foul vaginal discharge: Tumour tissue breaks down and releases fluid or blood-tinged discharge. Cancer.gov

3. Pelvic pain or pressure: A growing mass stretches uterine walls and nearby tissues. Cancer.gov

4. Pelvic mass or enlarged uterus: The tumour can make the uterus feel bigger on exam. Cancer.gov

5. Pain with sex (dyspareunia): Inflammation, bleeding, or tumour near the cervix can make intercourse painful. Cancer.gov

6. Fatigue and weakness: Ongoing bleeding can cause anemia; cancer can also cause general tiredness. Cancer.gov

7. Unintentional weight loss: Advanced cancer uses body energy and reduces appetite. Cancer.gov

8. Lower abdominal bloating: Mass effect or fluid in the abdomen (ascites) in advanced disease. Cancer.gov

9. Frequent urination or urgency: The enlarged uterus presses on the bladder. Cancer.gov

10. Constipation: Pressure on the rectum or pelvic nerves. Cancer.gov

11. Back or hip pain: Spread to pelvic sidewall or bone can cause referred pain. Cancer.gov

12. Leg swelling: Tumour can block pelvic lymph or veins; clots can also occur. Cancer.gov

13. Shortness of breath or cough: If cancer spreads to lungs, breathing symptoms may appear. Cancer.gov

14. Nausea or poor appetite: Due to advanced disease or treatment-related effects (if already diagnosed). Cancer.gov

15. No symptoms at first: Some tumours are found on a scan or after testing for mild spotting. Absence of symptoms does not exclude disease. Cancer.gov

---

Diagnostic tests

Diagnosis has three goals: confirm cancer, stage how far it has spread, and guide treatment. Staging for carcinosarcoma follows endometrial carcinoma rules (FIGO), and management is aligned with high-risk endometrial cancer in many guidelines. PubMed+1

A) Physical examination

1. General exam and medical history: The clinician asks about bleeding, pain, medicines (e.g., tamoxifen), menopause timing, and family history. They check vital signs, weight, and signs of anemia. This builds the first clinical picture. Cancer.gov

2. Abdominal and pelvic exam: The doctor gently presses the abdomen for masses and tenderness. A speculum exam looks for bleeding source and a bimanual exam feels the uterus and ovaries for size and mobility. This can reveal an enlarged, irregular uterus or a mass. Cancer.gov

3. Rectovaginal exam: A finger in the vagina and rectum at the same time checks the tissue behind the uterus and pelvic ligaments for nodules or fixation that suggest spread. Cancer.gov

B) Manual/procedural office tests

4. Transvaginal ultrasound (TVUS): A small probe in the vagina uses sound waves to show the uterus. A thickened endometrium or polypoid mass raises concern. TVUS is a fast, first-line test for abnormal bleeding. Cancer.gov

5. Saline-infusion sonohysterography: Sterile fluid is placed into the uterus during ultrasound to outline the cavity. It helps show intracavitary masses or irregularities. Cancer.gov

6. Endometrial biopsy (office pipelle): A thin straw-like tube samples the uterine lining. Pathology may show high-grade carcinoma and sarcomatous areas. Sometimes the sarcoma part is missed in small samples, so further tissue is needed. Biopsy is essential for diagnosis. Cancer.gov

7. Hysteroscopy with dilation & curettage (D&C): A tiny camera looks inside the uterus and a larger tissue sample is scraped or suctioned. This improves diagnostic accuracy when office biopsy is inconclusive. Cancer.gov

8. Cervical cytology/HPV testing (adjunct): Not a diagnostic test for this tumour but may be performed during evaluation; abnormal cells shed to the cervix are uncommon yet possible. Cancer.gov

C) Laboratory and pathological tests

9. Histopathology of curettings or tumour: The pathologist looks under the microscope and confirms both carcinoma and sarcoma components. They describe whether the sarcomatous part is homologous or heterologous and record margins, depth, lymphovascular invasion, and myometrial invasion in surgical specimens. This is the gold standard for diagnosis. PMC

10. Immunohistochemistry (IHC): Stains such as p53, p16, ER/PR, MMR proteins (MLH1, MSH2, MSH6, PMS2), and epithelial/mesenchymal markers help classify the epithelial component, detect mismatch repair deficiency (possible Lynch syndrome), and support the mixed nature of the tumour. PMC

11. Molecular testing (as available): Panels may identify TP53 mutations and other changes that align carcinosarcoma with serous-like high-risk endometrial cancers. Results can inform prognosis and clinical trials. PMC

12. Complete blood count (CBC): Looks for anemia from bleeding and white-cell/platelet changes. Baseline values help plan surgery and treatments. Cancer.gov

13. Comprehensive metabolic panel: Checks kidney and liver function before imaging with contrast and before chemotherapy planning. Cancer.gov

14. Coagulation profile: Ensures safe biopsy/surgery and screens for clot risks; pelvic cancers increase thromboembolism risk. Cancer.gov

15. Tumour markers (selective): CA-125 may be elevated but is non-specific. It can help follow disease over time in some patients; it does not diagnose on its own. Cancer.gov

D) Electrodiagnostic tests

Electrodiagnostic studies are not routine for diagnosing this uterine tumour. They are used only if symptoms suggest nerve or muscle involvement.

16. Electrocardiogram (ECG) pre-treatment: Not a cancer test, but often done before anaesthesia or chemotherapy (e.g., if anthracyclines are considered later). It establishes heart rhythm status. Cancer.gov

17. Nerve conduction/electromyography (rare): Considered only if there are unusual nerve symptoms from pelvic compression or metastasis; not standard. Cancer.gov

E) Imaging tests

18. Pelvic MRI with contrast: Best for mapping tumour size, depth of myometrial invasion, and cervical involvement. It helps surgeons plan the operation and lymph node assessment. PubMed

19. Contrast-enhanced CT of chest/abdomen/pelvis: Looks for spread to lymph nodes, lungs, liver, and peritoneum. It is a common staging tool, especially if high-risk features are suspected. Cancer.gov

20. PET-CT (selected cases): Helps assess active disease or unclear findings on CT/MRI, especially in suspected recurrence. It is not mandatory for all patients. Cancer.gov

21. Transvaginal ultrasound (initial imaging): Already mentioned as a manual test; it also belongs to imaging because it is a diagnostic scan. It is useful to flag endometrial thickness and masses. Cancer.gov

22. Chest X-ray: A simple way to screen for lung spread if CT is not immediately available; CT is more sensitive. Cancer.gov

23. Cystoscopy/colonoscopy (only if indicated): Performed if there are symptoms or imaging signs of bladder or bowel invasion; not routine otherwise. Cancer.gov

Treatment overview

Most patients who can safely have surgery undergo total hysterectomy with bilateral salpingo-oophorectomy and surgical staging, often with lymph node assessment and omental evaluation. Because carcinosarcoma behaves like a high-risk endometrial cancer, adjuvant or systemic chemotherapy is standard in most stage II–IV and often considered in stage I high-risk disease. The modern preferred regimen is carboplatin + paclitaxel, based on a large phase III trial (NRG-GOG-0261) showing longer progression-free survival and non-inferior overall survival versus ifosfamide-paclitaxel. Radiation may be used for pelvic control. nrgoncology.org+2NCCN+2

---

Non-pharmacological treatments

1. Surgery (primary cytoreductive hysterectomy with BSO and staging): Removes the visible tumor and provides exact stage; cornerstone of care when feasible. PMC+1

2. Adjuvant pelvic radiotherapy / vaginal cuff brachytherapy (when indicated): Lowers local pelvic/vaginal recurrence risk; often paired with chemotherapy for high-risk disease. Cancer.gov

3. Palliative radiation to symptomatic sites: Relieves pain or bleeding from localized recurrences or metastases. Cancer.gov

4. Nutritional optimization and anemia correction: Iron therapy, transfusion when needed, and dietitian-guided protein-calorie support improve strength for surgery and chemo. Cancer.gov

5. Prehabilitation (light aerobic and strength exercise before treatment): Improves surgical recovery and chemotherapy tolerance when time allows. Cancer.gov

6. Smoking cessation and alcohol moderation: Supports wound healing, cardiopulmonary fitness, and reduces treatment complications. Cancer.gov

7. Thrombosis prevention measures: Early ambulation and compression devices (and pharmacologic prophylaxis when prescribed) reduce clot risks in pelvic surgery and chemo. Cancer.gov

8. Pain and symptom control (non-opioid base with escalation as needed): Multimodal analgesia, antiemetics, bowel regimens improve quality of life during active therapy. Cancer.gov

9. Psychological support and counseling: Anxiety and depression are common; counseling and support groups help adherence and coping. Cancer.gov

10. Fertility/menopause and sexual health counseling (as applicable): Explains surgical menopause and addresses body image, dryness, and intimacy concerns early. Cancer.gov

11. Palliative care integration for advanced disease: Early palliative care improves symptom control and often quality of life and satisfaction. Cancer.gov

12. Clinical trial participation: Strongly encouraged whenever available because UCS is rare and trials can improve access to modern therapies. NCCN

---

Drug options

(Most patients get carboplatin + paclitaxel after surgery or for advanced disease. Below are important agents with label references. Some are used off-label in UCS but supported by endometrial-cancer guidelines—your oncology team individualizes choices. Doses/timing are examples from labels or common practice; individual plans vary.)

1. Carboplatin (platinum agent): Backbone of first-line therapy with paclitaxel. Dosed by AUC (e.g., AUC 5–6 IV q3wk). Main actions: DNA cross-linking → cancer-cell death. Key risks: low blood counts, nausea, kidney function considerations, allergic reactions after multiple cycles. FDA Access Data+1

2. Paclitaxel (taxane): Partner drug with carboplatin (e.g., 175 mg/m² IV q3wk). Stabilizes microtubules and stops cell division. Hypersensitivity reactions require premedication; also causes neuropathy and low counts. FDA Access Data+1

3. Ifosfamide: Historical regimen (often with paclitaxel). Alkylates DNA; dose and schedule vary. Notable toxicities: myelosuppression, encephalopathy, hemorrhagic cystitis (needs mesna protection). FDA Access Data+1

4. Cisplatin: Alternative platinum with more kidney/nerve toxicity than carboplatin; used selectively. Requires hydration and monitoring. FDA Access Data+1

5. Doxorubicin (anthracycline): Sometimes used in sarcoma-leaning regimens or later lines; intercalates DNA/topoisomerase II inhibition. Cardiac monitoring is important. FDA Access Data

6. Docetaxel: A taxane alternative if paclitaxel neuropathy is problematic; same microtubule mechanism, with neutropenia as a key toxicity. (FDA-labeled broadly for other cancers; used off-label per clinician judgment in endometrial contexts.) FDA Access Data

7. Gemcitabine: Antimetabolite sometimes used with docetaxel for sarcomas; myelosuppression and fatigue are common. (Label supports use in other tumors; used selectively in UCS.) PMC

8. Pembrolizumab + Lenvatinib (for pMMR/MSS advanced endometrial cancer after prior therapy): Pembrolizumab 200 mg q3wk (or 400 mg q6wk) IV plus lenvatinib 20 mg orally daily. This combo has full FDA approval for advanced endometrial carcinoma that is pMMR/not MSI-H after prior systemic therapy; key risks: hypertension, fatigue, diarrhea, hand-foot syndrome, immune-related adverse events. FDA Access Data+2U.S. Food and Drug Administration+2

9. Pembrolizumab + carboplatin + paclitaxel (first line for primary advanced/recurrent endometrial carcinoma): FDA-approved June 17, 2024; pembrolizumab is continued as single agent after chemo. Immune-related adverse events need early recognition. U.S. Food and Drug Administration

10. Dostarlimab (dMMR/MSI-H endometrial cancer): Anti-PD-1 antibody approved as monotherapy after platinum and, in 2024, with carboplatin-paclitaxel first-line for advanced or recurrent EC. Immune toxicities are similar to pembrolizumab. FDA Access Data+1

11. Bevacizumab (anti-VEGF): Sometimes added for recurrent disease in endometrial cancer; watch for hypertension, proteinuria, bleeding risk. (Label is for other cancers; use is case-by-case in EC/UCS.) Cancer.gov

12. Trastuzumab (HER2-positive serous-like tumors): For HER2-amplified uterine serous carcinomas, adding trastuzumab to carboplatin-paclitaxel improves outcomes; some carcinosarcomas express HER2, so testing can be considered. (Label is for breast/gastric; EC use is guided by data and guidelines.) Cancer.gov

The NRG-GOG-0261 phase III trial showed improved progression-free survival and non-inferior overall survival compared with ifosfamide-paclitaxel and with less toxicity burden; major guidelines and patient guides list carbo-taxol as the preferred regimen. nrgoncology.org+1

---

Surgeries (what they are and why done)

1. Total hysterectomy with bilateral salpingo-oophorectomy (TAH-BSO): Removes the uterus, cervix, both ovaries, and tubes; establishes diagnosis, controls bleeding, and is the main potentially curative step in early disease. PMC

2. Surgical staging and node assessment (pelvic ± para-aortic): Defines spread and helps decide who needs chemo and/or radiation. PMC

3. Infracolic omentectomy/omentectomy: The omentum is a frequent site of spread in high-grade endometrial cancers; removing or sampling it aids staging. PMC

4. Debulking (cytoreduction) for advanced/metastatic disease: Reducing visible tumor may improve symptoms and can support better outcomes alongside systemic therapy. PMC

5. Fertility-sparing approaches: Generally not recommended in carcinosarcoma given its aggressiveness; included here to clarify counseling and set expectations. Cancer.gov

---

Prevention and risk-reduction ideas

These steps cannot guarantee prevention, but they reduce overall endometrial cancer risk or help detect problems early:

1. Report any post-menopausal bleeding immediately. Early biopsy finds cancer sooner. Cancer.gov

2. Manage weight and metabolic health. Obesity increases endometrial cancer risk. Cancer.gov

3. Balance estrogen with progestin when needed. If you use estrogen therapy and still have a uterus, ensure progestin protection. Cancer.gov

4. Discuss tamoxifen risks/benefits with your doctor. Rarely, long use can raise endometrial cancer risk. Cancer.gov

5. Quit smoking and limit alcohol. Supports healing and reduces general cancer risks. Cancer.gov

6. Control blood pressure and diabetes. Improves surgical and chemo safety. Cancer.gov

7. Stay up-to-date with gynecologic visits. Persistent bleeding or discharge deserves prompt evaluation. Cancer.gov

8. Exercise regularly. Physical activity supports hormone balance and overall health. Cancer.gov

9. Know your family history. Rare hereditary syndromes (e.g., Lynch) can raise endometrial risks; ask about genetic counseling if relevant. Cancer.gov

10. Consider clinical trials if at risk or diagnosed. Trials offer access to new approaches. NCCN

---

When to see a doctor (urgent and routine triggers)

Seek care now for any post-menopausal bleeding, heavy bleeding with clots, new pelvic pain/pressure, unexplained weight loss, severe fatigue from suspected anemia, or persistent watery/bloody discharge. If you already have a diagnosis, contact your team immediately for fever, chest pain, shortness of breath, uncontrolled pain, swelling/redness in a leg (possible clot), or new neurologic symptoms. These can be emergencies during chemo or after surgery. Cancer.gov

---

What to eat and what to avoid (supportive, simple guidance)

There is no anti-cancer “magic” diet, but balanced, high-protein meals help healing and strength. Aim for lean proteins, legumes, whole grains, colorful fruits/vegetables, and adequate fluids. If appetite is low during treatment, use small frequent meals and oral nutrition supplements as advised. Avoid undercooked foods when neutropenic, excessive alcohol, high-dose herbal products without oncologist approval, and very restrictive fad diets that cause weight loss and weakness during therapy. A registered dietitian is extremely helpful. Cancer.gov

---

FAQs

1. Is uterine carcinosarcoma the same as endometrial cancer?
   It is a rare, very aggressive endometrial-type cancer with both carcinoma and sarcoma parts; it is now staged and largely treated like high-grade endometrial cancer. Cancer.gov

2. How common is it?
   It is rare compared with other uterine cancers, but it carries a higher risk of spread and recurrence. Cancer.gov

3. What is the main treatment?
   Surgery (TAH-BSO with staging) followed by chemotherapy in most patients; carboplatin + paclitaxel is the current standard. nrgoncology.org+1

4. Do I need radiation?
   Many patients benefit from pelvic or vaginal cuff radiation to reduce local recurrence, often combined with chemo; your team individualizes this. Cancer.gov

5. Can immunotherapy help?
   Yes, for biomarker-selected patients (dMMR/MSI-H) or in combinations approved for endometrial cancer; pembrolizumab or dostarlimab may be used per label and guidelines. U.S. Food and Drug Administration+1

6. What about pembrolizumab + lenvatinib?
   This combination is FDA-approved for advanced endometrial carcinoma that is pMMR/not MSI-H after prior therapy; it’s an option some UCS patients may receive. FDA Access Data

7. Will I lose my fertility?
   Because the uterus and ovaries are removed for cure, fertility is lost; fertility-sparing is generally not advised in carcinosarcoma. Cancer.gov

8. What are survival outcomes?
   Outcomes vary by stage; UCS has poorer survival than typical endometrioid cancers, making prompt combined therapy important. ScienceDirect

9. How many chemo cycles are typical?
   Commonly 6 cycles of carboplatin + paclitaxel (exact plan varies). Monitoring manages side effects like low counts and neuropathy. NCCN

10. What side effects should I expect?
    Fatigue, hair loss, low blood counts, nausea, neuropathy (taxanes), and risk of allergic reactions to platinums; your team provides premedication and monitoring. FDA Access Data+1

11. Is HER2 testing useful?
    Some high-grade endometrial tumors are HER2-positive; if so, trastuzumab with chemo may be considered. Ask your oncologist about testing. Cancer.gov

12. How is follow-up done?
    Regular visits with symptom review and pelvic exam; imaging when symptoms or exam suggest recurrence. Cancer.gov

13. Can lifestyle changes help during treatment?
    Yes: gentle activity, sleep, nutrition, and stopping smoking help your body tolerate therapy and recover. Cancer.gov

14. Are there clinical trials for me?
    Trials are strongly encouraged for this rare cancer; ask your center or check national registries. NCCN

15. What if I can’t have big surgery?
    Your team can use tailored combinations of limited surgery, radiation, and systemic therapy to control disease and symptoms. Cancer.gov

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: November 11, 2025.

PDF Documents For This Disease Condition References